At a glance
- Originator GlaxoSmithKline
- Class Analgesics
- Mechanism of Action Neurokinin 3 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 23 Feb 1995 Preclinical development for Undefined in United Kingdom (Unknown route)